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Abstract
Background: 5-AzaCytidine (AzaC) is a DNA demethylating drugs that has been shown to inhibit
cell growth and to induce apoptosis in certain cancer cells. Induced expression of the galectin1
(Gal1) protein, a galactoside-binding protein distributed widely in immune cells, has been described
in cultured hepatoma-derived cells treated with AzaC and this event may have a role in the effect
of the drug. According to this hypothesis, we investigated the effect of AzaC and Gal1 on human
lymphoid B cells phenotype.
Methods: The effect of AzaC and Gal1 on cell growth and phenotype was determined on the
Burkitt lymphoma cell line BL36. An immunocytochemical analysis for detection of Gal1 protein
expression was performed in AzaC-treated cells. To investigate the direct effects of Gal1,
recombinant Gal1 was added to cells.
Results: Treatment of lymphoid B cells with AzaC results in: i) a decrease in cell growth with an
arrest of the cell cycle at G0/G1 phase, ii) phenotypic changes consistent with a differentiated
phenotype, and iii) the expression of p16, a tumor-suppressor gene whose expression was
dependent of its promoter demethylation, and of Gal1. A targeting of Gal 1 to the plasma
membrane follows its cytosolic expression. To determine which of the effects of AzaC might be
secondary to the induction of Gal1, recombinant Gal1 was added to BL36 cells. Treated cells
displayed growth inhibition and phenotypic changes consistent with a commitment toward
differentiation.
Conclusions: Altered cell growth and expression of the cell surface plasma cell antigen, CD138
are detectable in BL36 cells treated by AzaC as well as by Gal1. It seems that AzaC-induced Gal1
expression and consequent binding of Gal1 on its cell membrane receptor may be, in part, involved
in AzaC-induced plasmacytic differentiation.
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Introduction
DNA methylation is involved in cellular development,
differentiation and transformation [1]. In different types
of tumours, aberrant methylation of CpG islands in the
promoter region has been observed for many differentia-
tion- and cancer-related genes resulting in the silencing of
their expression [2]. Therefore, over the past decade, there
has been increasing interest in the use of demethylating
agents to induce the differentiation or the apoptosis of
cancer cells [3,4]. Treatment of the cells with the pyrimi-
dine analogue 5-AzaCytidine (AzaC), which inhibits
methylation of cytosine residues during replication in the
newly synthesised DNA, has been demonstrated to reacti-
vate the expression of many silenced genes, as well as the
expression of the silenced retro viral genomes [5]. Silenc-
ing of one of the most important cell cycle regulatory pro-
teins p16INK4a by methylation of the CpG islands in the
promoter region has been found to be a common event in
tumours [6,7]. Protein p16 suppresses S-phase entry by
antagonising the cyclin-dependent kinases CDK4 and
CDK6 [8].
Deciphering the molecular mechanisms underlying the
phenotypic effects of the treatment with demethylating
drugs is a crucial step in understanding what genes may be
interesting targets for chemotherapy. The available data
on the mechanism of action of these drugs strengthen the
idea that it is different from that of agents that act prima-
rily via their cytotoxic effects, such as Arc-C [9]. Several
lines of evidence suggest that galectin-1 (Gal-1), a 14 kDa
galactoside-binding protein distributed widely in im-
mune cells, could be involved in these mechanisms. Sev-
eral members of the galectin family have been found to
modulate cell differentiation and cell survival [10–15].
Early studies demonstrated that the expression of Gal1
could be induced in cultured hepatoma-derived cells by
treatment with AzaC [16]. Chiariotti and co-workers
showed that reactivation of the silent Gal1 alleles is ac-
companied by a transition from a fully methylated to a
fully unmethylated state of several CpG dinucleotides in
the promoter region [17]. In addition, nonexpressing tis-
sues exhibited highly heterogeneous methylation profiles
[18]. Gal is considered to be a typical cytosolic protein,
lacking a signal peptide for membrane translocation [19].
However, most of the functions assigned to galectins are
confined to the cell surface or extracellular milieu
[10,20,21], consistent with evidences for extracellular
roles of Gal1 in regulation of cellular differentiation and
proliferation. It is clear that Gal1 can be specifically secret-
ed and targeted by an infrequent mechanism [22–24]. The
constitutive expression as well as the secretion of Gal1
dramatically depend on cell types [25] and are responsive
to developmental events [20,22,23].
An example is found during erythroid differentiation of
the K562 human leukaemia cell line. During differentia-
tion induced by erythropoietin and deprivation of granu-
locyte-macrophage colony-stimulating factor, the cells
empty their cytoplasmic content of endogenous Gal1 into
the external medium where it is bind to cell surface recep-
tors [24]. The synthesis and secretion of Gal1 by leuko-
cytes are of interest because lactosaminoglycans present at
the leukocyte cell surface may be physiologically signifi-
cant galectin receptors that could mediate autocrine or
paracrine functions. Several lines of evidence indicate that
Gal1 may function as an autocrine negative growth regu-
lator or as a pro-apoptotic factor [26–28]. We have recent-
ly demonstrated that Gal1 binding to Burkitt lymphoma
cells results in an intracellular signal, with inhibition of
the tyrosine phosphatase activity of CD45 and therefore
phosphorylation of Lyn kinase [29,30].
In this work, we study the effect of AzaC treatment on the
lymphoma cell line BL36. As p16INK4a gene has been
found to be downregulated by hypermethylation at high
frequency in different types of tumours [6,7], it is used as
a control of AzaC effect. Then, the phenotypic effects of
AzaC are compared to those obtained by the addition of
exogenous Gal1. The findings that we report here lend fur-
ther support to a potential role for Gal1 in the AzaC-in-
duced pathway of differentiation in hematopoietic cells.
Materials and Methods
The BL36 B lymphoma cell line [31], a gift from Pr. Lenoir
(CIRC, Lyon, France) to Pr. M. Raphael, was maintained
in a complete medium of RPMI 1640, containing 10%
heat-inactivated foetal calf serum, 2 mM L-Glutamine, 1
mM sodium pyruvate (complete medium). Treatment
with AzaC was conducted as follows: 24 hours after seed-
ing 5, 10 or 50 µM of AzaC were added to 5 ml of com-
plete medium [16,32]. The cells were feeded with the
appropriate medium during the time of the experiments.
Several independent methods were used to assess the pro-
liferative versus death states of the cells. For direct deter-
mination of cell number, at the indicated time point the
cells were harvested and counted using a Coulter Counter
(Beckman Coulter France, Villepinte, France). Determina-
tion of the viable cell numbers used propidium iodide
(PI) (Sigma, Saint-Quentin Fallavier, France). To deter-
mine the percent cell death including both apoptotic and
necrotic cells, AzaC-treated cells were analyzed for Annex-
inV binding and PI uptake as described [33] using the
ApoDetect AnnexinV-FITC kit (Zymed). Briefly, after
washing of cultured cells (3.105) with PBS and resuspen-
sion in binding buffer, the cells were stained with 10 µl
FITC-labelled AnnexinV and 10 µl PI (20 µg/ml). After 5
min of incubation at room temperature in the dark, again
200 µl of binding buffer was added and cells were ana-Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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lyzed by flow cytometry. The percent cell death was calcu-
lated by determining the percent of viable cells:
The MTS assay (CellTiter 96™, Promega, Charbonnières,
France) [34] was used to compare the percentage of meta-
bolically active cells in treated cells vs. untreated cells, as
previously described [14]. To study the cell cycle, 2.106
BL36 cells were pelleted at 1000 g for 5 minutes and the
pellet was incubated in a mixture of ethanol-PBS (70/30
v/v). The cells were pelleted another time and suspended
in 800 µl PBS. One hundred microliters of 1 mg/ml RNase
was added to the cell suspension. One hundred microlit-
ers of 400 µg/ml PI was added to the solution to stain the
nuclear DNA. The DNA content of the cells was deter-
mined by a flow cytometer, FACScan (Becton Dickinson,
Mountain View, CA), and the percentages of cells in
G0+G1, S, and G2+M phases of the cell cycle were ana-
lyzed by a polynomial model (SFIT, Becton Dickinson).
To determine the cell phenotypes, cells were suspended in
PBS supplemented with 2% BSA, and incubated in sus-
pension for 30 min with the fluorescently tagged primary
antibody or negative control, or incubated with untagged
antibody, washed, and incubated again for 30 min with
FITC-conjugated second antibody. All incubations were
performed at 4°C. Flow cytometry was performed using a
Coulter Epics Elite ESP instrument.
Human recombinant Gal1 (rGal1) was obtained as de-
scribed elsewhere [14]. The protein was purified by affin-
ity chromatography on a lactosyl-divinylsulfone-agarose
column. Antibodies against human Gal1 were generated
as described in [35] and [36]. The immunolocalization of
Gal1 was carried out as described for K562 cells [24].
For the preparation of cell extracts, a total of 17.106 cells
were solubilized in 1 ml of extraction buffer: 50 mM Tris
pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% SDS (w/v),
0.5% sodium deoxycholate (w/v), 0.5% Nonidet NP40
(v/v). Finally, 1 tablet of antiprotease cocktail (Roche,
Meylan, France) was added to 10 ml of buffer. The cells
were sonicated in ice three times. The lysat was centri-
fuged at 100, 000 g for 15 min at 4°C. The supernatant
was collected and stored at -20°C until used. Proteins were
resolved by discontinuous SDS-PAGE on 1.5 mm gel (T:
6–18%) according to the method of Laemmli. [37]. For
Western blotting, proteins separated by SDS-PAGE were
electrotransferred onto Immobilon-P membrane (Milli-
pore). Blots were incubated with 1:50 anti-Gal1 mAb, or
1:500 anti-pl6 mAb (Pharmingen) for 2 h at room tem-
perature. The blots were developed with anti-mouse Ig an-
tibody-HRP diluted 1/10,000, followed by incubation in
the Amplified Opti-4CN kit substrate (Bio-Rad). The im-
age of the membranes was acquired from GS-700 Densit-
ometer 4, and analyzed with Molecular Analyst Software
(Bio-Rad).
Results
During the four days of treatment with AzaC, cell prolifer-
ation appeared to slow (Fig. 1A). When BL36 cells were
cultured with AzaC at the high concentration of 50 µM,
cell proliferation was strongly inhibited. BL36 cells ex-
posed to 5 µM AzaC also exhibited a significant reduced
growth rate but these cells were >95% viable by propid-
ium iodide test even at day 4 (data not shown), and were
found metabolically active by MTS assay as described be-
low. According to these results, the following experiments
addressing metabolic activity, death, and cell differentia-
tion were performed.
The proportion of metabolically active cells was deter-
mined using the MTS test in cultures treated with AzaC in
comparison with untreated cells (Fig. 1B). The cellular
conversion of MTS to the ultraviolet-absorbing formazan
product has been demonstrated to be directly proportion-
al to cellular metabolism resulting in the formation of re-
ducing equivalents such as NADH or NADPH [38]. A drop
in the % of metabolically active cells of about 36% was
observed over the 24 h period following the addition of
10 µM AzaC, and went up to 42% in cells treated with 50
µM AzaC. Cell death was confirmed by an increase in an-
nexinV/PI staining (Fig. 2). Within 48 h of incubation
with AzaC at 10 µM, the number of AnnexinV+ PI- apop-
totic cells and AnnexinV+ PI+ necrotic cells increased. For
longer incubation times, induced cell death increased dra-
matically.
Studies investigating the mechanisms whereby B lympho-
ma cells are induced to undergo apoptosis demonstrated
that an arrest in the cell cycle preceded apoptosis [39]. To
determine whether AzaC modified the cell cycle distribu-
tion of BL36 cells, the DNA content of AzaC-treated cells
was analyzed by PI staining. Cells were exposed to 10 µM
AzaC for 2, 4 and 7 days. After 7 days, AzaC-treated cells
exhibited a relative increase of cells in G0/G1 (77 %) in
comparison with controls (56%). In the same time, the
percentage of cells in the S phase compartment drops
from 38 to 18%, suggesting an accumulation of cells into
the G1 phase of the cell cycle (Fig. 3). However, there was
no change in the relative cell cycle distribution at 2 or 4
days after AzaC treatment. By this time, a significant pop-
ulation of cells has undergone apoptosis. This suggests
that, at least during the first days of treatment, inhibition
of growth is uncoupled with an arrest in the cell cycle.
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Figure 1
Effect of AzaC and Gal1 on growth and viability of BL36 cells in culture. A. The cells were seeded at 4 ×  105/ml and exposed to
AzaC at various concentrations for zero to 4 days. Cells were counted every day on a Coulter Counter. B. Cells were cultured
in triplicate in the presence or absence of AzaC. Metabolic activity was measured at the indicated times by the MTS assay.
Results are given as mean percentage of metabolically active cells (%) in cells grown in the presence of AzaC compared to cells
grown in the absence of AzaC. C. Cells grown in the presence of various concentrations of Gal1 were compared to control
cells. The data represent the mean of 3 experiments.Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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The effects of different concentrations of AzaC (5, 10, and
50 µM) on the expression of various surface antigen of
BL36 cells were investigated. AzaC increased the cell pop-
ulation that expressed the cell-surface maturation marker
CD23, CD30 present on activated B-lymphocytes [40]
and CD138 (Syndecan-1). After the treatment with 50 µM
Figure 2
Induction of cell death in cells treated by either AzaC or rGal1. The BL36 cell line was treated with 10 µM AzaC, 700 nM
rGal1, or buffer control and the percent cell death was evaluated by annexinV/propidium iodide staining, as described in "Mate-
rials and Methods". There is a dramatic increase in annexinV+/propidium iodide+ cells in the BL36 samples treated with AzaC,
not seen with the cells treated with Gal1.Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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Figure 3
Cell cycle analysis of AzaC-treated and control cells. The BL36 cells were incubated for 7 days in the presence of 10 µM AzaC
and the DNA contents were measured.Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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AzaC some changes were observed that were not detected
at lower concentrations: an increase of the cell population
that expressed CD21, and a decrease of the cell population
that expressed CD19 that is lost on maturation to plasma
cells [41], and CD71 that is expressed on proliferating
cells [42] (Table 1).
P16 is a biochemical marker of cell cycle progression [43]
and is also commonly utilized as a marker of demethyla-
tion reaction [44]. Consequently, we examined the effects
of AzaC treatment on expression of p16 in BL36 cells. As
expected, when these cells were treated with AzaC for 48
h, we detected the presence of p16 by Western Blotting
(Fig. 4A). Thus, taken together the data showed that AzaC
treatment induced an inhibition of cell growth related to
an arrest at G0/G1 phase of the cell cycle, and confirmed
the efficiency of AzaC treatment for expressing the tumour
suppressor gene p16.
To determine whether AzaC is able to induce the expres-
sion of Gal1 in B lymphoma cells, protein extracts pre-
pared form cells treated with 5–10 µM AzaC and from
untreated cells were separated by SDS-PAGE and analyzed
by immunoblotting with anti-Gal1 antibody. Fig. 4B,C
shows the rate of variation in Gal1 expression induced by
the differentiating agent. The galectin was not detected ei-
ther in untreated BL36 cells or BL36 cells treated with
AzaC for 24 or 48 h. The galectin became detectable in
AzaC-treated cells by 96 h. Then, to determine whether
the newly synthesised galectin molecules in AzaC-treated
BL36 cells are expressed on the cell surface, the binding of
anti-Gal1 Ab to untreated and treated BL36 cells was stud-
ied by immunocytochemistry. To visualize only extracel-
lular Gal1, cultures of BL36 cells were incubated with anti-
Gal1 antibody without permeabilization of their mem-
branes. Over the 4-day time-course, AzaC-induced Gal1
did progressively localise to the cell surface. However,
Gal1 did not exclusively localise to the cell surface but was
also distributed throughout the cytoplasm (Fig. 5).
Several of the changes in AzaC-treated BL cells might be
attributed directly to Gal1 induction, as Gal1 has been im-
plicated in differentiation and growth inhibition [11–
13,29,45,46]. A series of experiments were thus per-
formed to address whether changes observed in BL36
were direct AzaC effects and/or secondary effects related to
Gal1 expression induced by AzaC treatment. To this end,
BL36 was treated with recombinant Gal1 (rGal1). Slower
growth rates were confirmed for the rGal1-treated cul-
tures. A drop in the % of metabolically active cells of
about 28% was observed over the 24 h period following
the addition of 700 nM rGal1. However the proportion of
metabolically active cells in cultures treated with rGal1 vs.
the proportion in untreated cultures was not modified af-
ter 4 days of treatment (Fig. 1C). Moreover the variation
of cell death detected in treated-cells relative to the control
cultures was discrete (<10%) and limited to the first day
after the treatment (Fig. 2). To determine whether the in-
hibition of proliferation could be correlated to a modified
phenotype, the effects of 700 nM rGal1 on the expression
of various surface antigens shown to be modified or not
by AzaC were investigated. The populations of cells that
expressed CD19, CD23, CD45RO and CD45RA were un-
changed. On the other hand, 24 h rGal1 treatment in-
creased the cell population expressing CD138 (Fig. 6), a
marker for plasma cells, while it decreased the expression
of CD71. These modifications were reinforced after 48 h
rGal1 treatment (Table 2).
Discussion
In 1994, Chiariotti et al. [16] first reported experimental
data showing that the expression of Gal1 can be induced
in cultured hepatoma-derived cells by treatment with
AzaC. Interestingly, Gal1 and AzaC individually have
Table 1: Modulation of urface Markers on BL36 Cells by AzaC
Surface marker Control Treatment AzaC = 5 µM AzaC- 10 µM AzaC = 50 µM
CD 19 94.9 88.5 86.1 58.1
CD 21 <20 <20 <20 20.3
CD 23 31.5 47.6 45.2 63.8
CD 30 <20 <20 48.4 21.5
CD 45 RA 76.7 74.4 71.2 64.6
CD 45 RO 21.4 35.1 33.3 38.5
CD 71 97.3 94.9 93.8 83.8
CD 138 <20 23.9 23.8 24.8
BL36 cells were exposed with 5 µM, 10 µM and 50 µM AzaC for 4 days. Then cell surface antigens were analyzed by flow cytometry. Values below 
20% were considered as negative. In the same conditions, CDs 3 and 10 remain negative, and no variability was observed for CDs 11 a, 18, 25, 38, 
44, 48, 54, 58, 77, 80, and 95.Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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Figure 4
Immunoblotting of p16 and Gal1 from extracts of BL36 treated by AzaC. After different periods of treatment by AzaC, cell
extracts were separated by SDS-PAGE, followed by electrophoretic transfer onto Immobilon-P membranes and immunostain-
ing with (A) anti-pl6, or (B) anti-Gal1 monoclonal antibodies. Hela cells extract and rGal1 were used as positive controls for
p16 and Gal1, respectively. (C) Representation of the variation of Gal1 expression in cells treated different times with 5 or 10
mM AzaC, using the analysis of the Western blots in Molecular Analyst software.Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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been shown to affect similar cell processes in cancer cells,
including differentiation, and growth inhibition [12–
15,27,29,46–51]. Available data are consistent with the
suggestion that the expression of Gal1, accompanied by
its secretion and its binding to cell surface receptors, could
be involved in the AzaC observed effects in hematopoietic
cells where Gal1 modulates differentiation or apoptosis.
However, the mechanisms of these effects on hematopoi-
etic cells are unclear yet.
In the present study, the effects of AzaC, on the cell phe-
notype, cell differentiation and cell death of BL36 cells
were analyzed. The effects on cellular growth were time-
and dose-dependent. Five µM AzaC caused significant in-
hibition on cellular growth, but the cell viability remained
practically unchanged. AzaC increased the cell fraction in
the G0/G1 phases, suggesting that AzaC inhibits cell divi-
sion, which may be one of critical mechanisms of cell
modulation by AzaC. AzaC-treated cells initially may be-
come arrested at the G1 phase and then may either escape
to the cycle arrest or die due to mechanisms leading to
programmed cell death.
We also show that incubation of BL36 with AzaC induces
expression of Gal1. AzaC is thought to exert its effects as a
competitive inhibitor of cytosine methylation, resulting
in the expression of silenced genes. The gene for Gal1 is
one whose expression is possibly enhanced in this man-
ner. In the results reported here, we found that Gal 1 was
detected in cytosol after 120 h of treatment by 10 µM
AzaC and then Gal1 was externalized and bound to cell
surface receptors 24 h later. A key to understanding the ex-
tracellular biological functions of Gal1 is how its secretion
appears to be regulated and re-directed during develop-
ment and differentiation. Gal1 is likely released form ves-
icles close to the plasma membrane. On the basis of the
data, we propose that the released Gal1 be immediately
recruited to modulate cell activity. Gal1 may do this by in-
teracting with and modulating cell receptors via its carbo-
hydrate recognition domains because the Gal1-receptor
interaction is abrogated by thiodigalactoside [29].
Others and we have previously reported that Gal1 binds
to T and B lymphoblastoid cells [29,52,53]. Other studies
have demonstrated that galectins are immunosuppressive,
Figure 5
Immunoreactive localization of Gal1 in AzaC-treated BL36 cells. Cytospins were incubated with anti-Gal1 serum and peroxi-
dase-stained (original magnification 1250× ). First line: negative controls performed on untreated BL36 cells. No Gal1 was
detectable with anti-Gal1 antibody. Second line: permeabilized cells treated cells stained with monospecific anti-Gal1 antibody;
arrows indicate the localization of Gal1. Third line: after 144 h, Gal1 was detectable on the cell surface of nonpermeabilized
cells. No immunostaining was observed with controls performed with preimmune serum (not shown).Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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in animal models of autoimmune diseases [54–56].
Whereas the full role of Gal1 in modulating immune
function is not yet understood, the increase in Gal1 ex-
pression by AzaC in BL cells suggests that Gal1 may play a
role in the behaviour of normal leukocytes and of tumour
cells.
What is the underlying mechanism? Although the regula-
tory machinery triggered by demethylating stimulus and
resulting in phenotype modifications is not yet elucidat-
ed, it probably involves the stimulation of a signalling cas-
cade that regulates cell proliferation and viability. A
recently proposed model for such a cascade suggests the
involvement of a cytoplasmic protein, AZ2 [57]. The ami-
no-terminal part of the AZ2 protein is homologous to the
previously reported TANK and I-TRAF, which participate
in the signal transduction cascade from the TNF-receptor
to the transcription factor NFkappaB. Demethylating
stimulus may also modify a pathway activated by the
membrane-anchored protein-tyro sine phosphatase
CD45. Engagement of CD45 is known to regulate Src ty-
rosine kinases phosphorylation, phospholipase Cγ  regula-
tion, inositol phosphate production, diacylglycerol
production, PKC activation, and calcium mobilisation
[58–60].
Increased synthesis and secretion of Gal1 by the cell could
account for part of the phenotypic alterations detected in
AzaC treated cells. Gal1-induced dimerisation and/or seg-
regation might inhibit the catalytic site in CD45, thereby
Figure 6
Modification of the expression of CD138 in rGAL1-treated cells. Cells incubated for 24 or 48 h with rGal1 (700 nM) were
stained with anti-CD138 antibody and analyzed by flow cytometry. Controls were performed in the absence of rGAL1. Repre-
sentative-histograms: x-axis, log of the fluorescence intensity; y-axis, number of events.
Table 2: Modulation of Surface Markers on BL36 Cells by rGal1
Surface Marker Control 24 h Treatment (% positive) 
rGal1 – 24 h
Control 48 h Treatment (% positive) 
rGal1-48 h
CD71 98.00 94.90 93.00 45.00
CD138 <20 20.20 25.00 70.00
BL36 cells were exposed with 700 nM rGal1 for 1 and 2 days. Then cell surface antigens were analyzed by flow cytometry. Values below 20% were 
considered as negative.Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/2
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blocking tyrosine phosphates activity. Because Gal1 bind-
ing to cell surface receptors results in tyrosine phosphor-
ylation [29,61], it may allow a kinase-dependent signal to
be transduced. Several studies have linked Gal1 expres-
sion with growth inhibition [27] and cell death [26,62].
However, the reports that some growth inhibitory agents
did not induce Gal1 expression indicated that Gal1 ex-
pression is not dependent on the cell's growth state in gen-
eral, through it may be involved in growth suppression
[63]. Moreover, it is likely that Gal1 acts in a manner to
regulate specific signal transduction processes that is de-
termined by the cell type and by the state of cell differen-
tiation. In this work, exogenous rGal1 added to BL cells
inhibited cell growth. Moreover, Gal1 as well as AzaC in-
duced an expression of the cell surface plasma cell anti-
gen, CD138, a phenotypic marker that identify cells with
plasmacytic differentiation [64]. This is consistent with
the hypothesis that AzaC and Gal1 share similar signals
for differentiation, however, since there was a significant
difference in the expression of CD19 and CD23 after AzaC
or Gal1 treatments it is likely that some pathways are spe-
cifically modified by AzaC. The mechanisms involved in
these different pathways, important in clinical therapy, re-
main to be elucidated in the future. Ongoing studies are
aimed at identifying as globally as possible the modifica-
tions resulting from AzaC treatment by using proteomics
[65].
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